Arcus Biosciences, Inc.
RCUSDrugs in Pipeline
7
Phase 3 Programs
5
Upcoming Catalysts
5
Next Catalyst
Jun 15, 2026
13wMarket Overview
Stock performance and key metrics
5 upcoming, 0 past
Zimberelimab
Non Small Cell Lung Cancer
Nab-paclitaxel
Metastatic Pancreatic Ductal Adenocarcinoma
Casdatifan
Metastatic Clear Cell Renal Cell Carcinoma
Domvanalimab
Advanced Upper Gastrointestinal Tract Adenocarcinoma
Quemliclustat
Gastrointestinal Tract Malignancies
Etrumadenant
Prostatic Neoplasms, Castration-Resistant
AB680
Metastatic Colorectal Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Zimberelimab | Phase 3 | Non Small Cell Lung Cancer | - | - |
Nab-paclitaxel | Phase 3 | Metastatic Pancreatic Ductal Adenocarcinoma | - | - |
Casdatifan | Phase 3 | Metastatic Clear Cell Renal Cell Carcinoma | - | - |
Domvanalimab | Phase 3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma | - | - |
Quemliclustat | Phase 3 | Gastrointestinal Tract Malignancies | - | - |
Etrumadenant | Phase 2 | Prostatic Neoplasms, Castration-Resistant | - | - |
AB680 | Phase 2 | Metastatic Colorectal Cancer | - | - |